References
- Mack KA, Zhang K, Paulozzi L, et al. Prescription practices involving opioid analgesics among Americans with medicaid. J Health Care Poor Underserved. 2015;26:182–198.
- American Society of Addiction Medicine. Opioid Addiction 2016 Facts & Figures. Available from: https://www.asam.org/docs/default-source/advocacy/opioid-addiction-disease-facts-figures.pdf.
- Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452.
- National Institute on Drug Abuse. Opioid overdose crisis. 2019. Available from: https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis.
- Green JL, Bucher Bartelson B, Le Lait MC, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Dependence. 2017;175:140–145.
- Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30:334–341.
- U.S. Food & Drug Administration. New safety measures announced for extended-release and long-acting opioids. 2018. Available from: https://www.fda.gov/drugs/information-drug-class/new-safety-measures-announced-extended-release-and-long-acting-opioids.
- Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122.
- Rossiter LF, Kirson NY, Shei A, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17:279–287.
- Yenikomshian MA, White AG, Carson ME, et al. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients. J Opioid Manag. 2017;13:291–301.
- White AG, Birnbaum HG, Rothman DB, et al. Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction. Appl Health Econ Health Policy. 2009;7:61–70.
- White AG, LeCates J, Birnbaum HG, et al. Positive subjective measures in abuse liability studies and real-world nonmedical use: potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. J Opioid Manag. 2015;11:199–210.
- U.S. Food & Drug Administration. Abuse-deterrent opioid analgesics. 2019. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep. 2016;65:1–49.
- IMS Health. National prescription audit and sales perspective, extended release opioids. 2017. Available from: https://www.iqvia.com/.
- National Institute on Drug Abuse. Drug-related hospital emergency room visits. 2011. Available from: https://www.drugabuse.gov/publications/drugfacts/drug-related-hospital-emergency-room-visits#references.
- U.S. Food and Drug Administration. Highlights of prescribing information, Oxycontin. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022272s027lbl.pdf.
- U.S. Food and Drug Administration. Highlights of prescribing information, Embeda. 2014. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022321s016lbl.pdf.
- United States Census Bureau. Mid-year population by single year age groups – custom region – United States. 2016. Available from: https://www.census.gov/data-tools/demo/idb/region.php?N=%20Results%20&T=15&A=separate&RT=0&Y=2016&R=-1&C=US
- Substance Abuse and Mental Health Services Administration. Results from the 2014 National Survey on Drug Use and Health. 2014. Available from: https://www.datafiles.samhsa.gov/study-dataset/national-survey-drug-use-and-health-2014-nsduh-2014-ds0001-nid16876.
- Rice B, Kirson N, Shei A, et al. Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin. 2015;31(4):779–784.
- Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016;100:275–286.
- ICER Institute for Clinical and Economic Review. Abuse deterrent formulations of opioids: effectiveness and value. 2017. Available from: https://icer-review.org/wp-content/uploads/2016/08/NECEPAC_ADF_Final_Report_08_08_17.pdf.
- Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. N Engl J Med. 2016;374:1480–1485.
- Wagner A. States address opioid epidemic with abuse deterrent formulation legislation [Internet]. MultiState. 2016. Available from: https://www.multistate.us/blog/insider/2016/05/states-address-opiod-epidemic-with-abuse-deterrent-formulation-legislation.
- Wagner A. States have stalled on potential opioid abuse solution: deterrent formulation drugs [Internet]. MultiState. 2017. Available from: https://www.multistate.us/blog/state-efforts-have-stalled-on-potential-opioid-abuse-solution-deterrent-formulation-drugs.
- Alpert A, Powell D, Pacula RL. Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids. National Bureau of Economic Research; 2017. (Report No.: 23031).